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the analysis.
Study design
The effectiveness study was based on a long-term observational study of a screening programme (from 1992 to 2000) . The length of and loss to follow-up were not reported, but the patients were followed until birth took place (for those who were pregnant) or until genetic counselling was provided (for those who were not pregnant).
Analysis of effectiveness
All of the women included in the initial study sample were accounted for in the effectiveness analysis. The primary health outcomes were: the number of carriers of an allele with 50 or more repeats, 55 or more repeats, and 200 or more repeats; the number of pregnancies and subsequent prenatal diagnosis procedures; and the transmission of an allele containing 50 or more repeats.
The analysis was carried out retrospectively on sub-groups of ethnic groups living in Israel.
Effectiveness results
There were 207 carriers of an allele with 50 or more repeats. This represented a prevalence of 1:69 (confidence interval, CI: 1:62 -1:83).
There were 127 carriers of an allele with 55 or more repeats. This represented a prevalence of 1:113 (CI: 1:96 -1:136).
Full allele mutation (200 or more repeats) was found in 3 women.
There were 193 pregnancies in 173 pregnant women and 177 (91.7%) prenatal diagnosis procedures were performed.
The allele with 50 or more repeats was transmitted in 90 pregnancies (50.8%), of which 5 expanded to the full mutation.
No full mutation was found in any of the foetuses of mothers with less than 70 repeats. There were no statistically significant differences in the diverse ethnic groups considered in the analysis.
Clinical conclusions
The observational study indicated that the prevalence of alleles was greater than studies had shown. A cut-off point of 55 (or even 60) repeats can be considered as safe for making a decision about the need for prenatal testing.
Modelling A decision tree model was constructed to estimate the net benefit of the screening programme in comparison with the no screening option. The tree comprised 132 branches, which represented all possible sequences of events. The structure of the tree was not depicted and further details were not provided. The model was populated with data from the current study and from the literature.
Outcomes assessed in the review
The outcomes assessed from the literature were the probabilities of: the rejection of a screening programme;
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not being a carrier among women who accepted screening;
the rejection of genetic counselling among carriers; a foetus that does not have the full fragile-X mutation when the mother is a carrier;
foetal diagnosis being rejected when the mother is a carrier;
finding a normal foetus following foetal diagnosis;
iatrogenic abortion following foetal diagnosis;
finding a somatic chromosome abnormality in the foetus at prenatal diagnosis;
finding a sex chromosome abnormality in the foetus at prenatal diagnosis;
finding the full fragile-X mutation in the foetus at prenatal diagnosis;
a pregnancy termination being rejected where there is a somatic-chromosome abnormality or a sex-chromosome abnormality in the foetus, or where the foetus has the full fragile-X mutation;
a foetus with the full fragile-X mutation being male; a mentally retarded male (or female) with the full fragile-X mutation;
the pregnancy being a second pregnancy; and screening being rejected in the second pregnancy where it was rejected in the first pregnancy.
Complementary values will not be reported in this abstract.
Study designs and other criteria for inclusion in the review
A review of the literature was not undertaken. The designs of the primary studies were not reported.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The probability values used in the decision model were derived from 5 studies.
Methods of combining primary studies
